<DOC>
	<DOC>NCT02198716</DOC>
	<brief_summary>The treatment of complex coronary disease causing limiting symptoms of angina with drug-eluting stent technology will prove superior to bare metal stent technology, with respect to a combined endpoint of mortality, MI, requirement for target vessel revascularisation and severe haemorrhage, in patients aged 80 or above.</brief_summary>
	<brief_title>Xience or Vision Stent Management of Angina in the Elderly</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>AGE&gt;80 Stable angina or acute coronary syndrome Coronary narrowing suitable for stenting that is either ≥15mm long and/or ≤3mm diameter. Any lesion with high risk of restenosis eg chronic total occlusion, bifurcation, severe calcification Any left main stem lesion Acute ST segment elevation myocardial infarction Cardiogenic shock Platelet count =50 x 109/mm3 Patient life expectancy &lt; 1 year Known allergies to clopidogrel, aspirin, heparin, stainless steel, IV contrast or stent drug elutant Recent major GI haemorrhage (within 3 months) Any previous cerebral bleeding episode Participation in another investigational drug or device study Patient unable to give consent Clinical decision precluding the use of drug eluting stent</criteria>
	<gender>All</gender>
	<minimum_age>80 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Percutaneous coronary intervention</keyword>
	<keyword>Elderly</keyword>
	<keyword>Angina</keyword>
</DOC>